Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21858972 | 1.00 | HTT (0.41) | HTTBACE1MEN1KMT2ALMNA | |
| SCHEMBL19239617 | 0.89 | BACE1 (0.40) | HTTBACE1MEN1KMT2ALMNA | |
| SCHEMBL12245284 | 0.89 | BACE1 (0.40) | HTTBACE1MEN1KMT2ALMNA | |
| SCHEMBL22283040 | 0.89 | BACE1 (0.40) | HTTBACE1MEN1KMT2ALMNA | |
| SCHEMBL22283041 | 0.89 | BACE1 (0.40) | HTTBACE1MEN1KMT2ALMNA | |
| SCHEMBL16500043 | 0.88 | HTT (0.39) | HTTBACE1MEN1KMT2ALMNA | |
| SCHEMBL2560115 | 0.88 | HTT (0.39) | HTTBACE1MEN1KMT2ALMNA | |
| SCHEMBL17196627 | 0.86 | MEN1 (0.45) | HTTBACE1MEN1KMT2ALMNA | |
| SCHEMBL17918547 | 0.86 | MEN1 (0.43) | HTTBACE1MEN1KMT2ALMNA | |
| SCHEMBL29895834 | 0.82 | BACE1 (0.37) | HTTBACE1MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912700-B2 | Anti-proliferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | PHEON THERAPEUTICS LTD (GB) | 2024-02-27 | — | — | US | disclosed |
| US-20240002379-A1 | ASYMMETRIC CONJUGATE COMPOUNDS | PHEON THERAPEUTICS LTD (GB) | 2024-01-04 | — | — | US | disclosed |
| WO-2023173096-A1 | PYRROLOBENZODIAZEPINE INTERMEDIATES AND USES THEREOF | SIGMA-ALDRICH CO. LLC (US) | 2023-09-14 | — | — | WO | disclosed |
| EP-3458069-B1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MERSANA THERAPEUTICS INC (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20230143309-A1 | PYRROLOBENZODIAZEPINE ANTIBODY CONJUGATES | MEDIMMUNE LIMITED (GB) | 2023-05-11 | — | — | US | disclosed |
| US-11524969-B2 | Pyrrolobenzodiazepines and conjugates thereof as antitumour agents | MEDIMMUNE LIMITED (GB) | 2022-12-13 | — | — | US | disclosed |
| US-11517626-B2 | Pyrrolobenzodiazepine antibody conjugates | MEDIMMUNE LIMITED (GB) | 2022-12-06 | — | — | US | disclosed |
| EP-3612537-B1 | PYRROLOBENZODIAZEPINE CONJUGATES | MEDIMMUNE LTD (GB) | 2022-07-13 | — | — | EP | disclosed |
| US-11370801-B2 | Pyrrolobenzodiazepine conjugates | MEDIMMUNE LIMITED (GB) | 2022-06-28 | — | — | US | disclosed |
| CN-108463253-B | Pyrrolobenzodiazepine conjugates | 麦迪穆有限责任公司 | 2022-03-04 | — | — | CN | disclosed |
| US-20180291021-A1 | PDD COMPOUNDS | PHEON THERAPEUTICS LTD (GB) | 2018-10-11 | — | — | US | disclosed |
| CN-108463253-A | Pyrrolobenzodiazepines * conjugates | 麦迪穆有限责任公司 | 2018-08-28 | — | — | CN | disclosed |
| CN-104837502-B | Pyrrolobenzodiazepines and conjugates thereof | 麦迪穆有限责任公司 | 2018-08-10 | — | — | CN | disclosed |
| US-20180177795-A1 | ISOQUINOLIDINOBENZODIAZEPINE (IQB)-1(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE (CBI) DIMERS | CELLERANT THERAPEUTICS, INC. | 2018-06-28 | — | — | US | disclosed |
| WO-2018069490-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | MEDIMMUNE LIMITED (GB) | 2018-04-19 | — | — | WO | disclosed |
| US-20170340752-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MEDIMMUNE LIMITED (GB) | 2017-11-30 | — | — | US | disclosed |
| WO-2017201132-A2 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| US-20170333442-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2017-11-23 | — | — | US | disclosed |
| WO-2017137553-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | MEDIMMUME LIMITED (GB) | 2017-08-17 | — | — | WO | disclosed |
| WO-2017137556-A1 | PYRROLOBENZODIAZEPINE ANTI-HER2 ANTIBODY CONJUGATES | ADC THERAPEUTICS SA (CH) | 2017-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180177795-A1 | ISOQUINOLIDINOBENZODIAZEPINE (IQB)-1(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE (CBI) DIMERS | BCL6B, HTR2B, IDO1 | HTT 1009/4885BACE1 1366/4885MEN1 2879/4885 |
| US-11524969-B2 | Pyrrolobenzodiazepines and conjugates thereof as antitumour agents | PBRM1, HDAC6, NPM1 | HTT 2272/4885BACE1 4096/4885MEN1 977/4885 |
| US-20170333442-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | CD79B, CLTB, FCGR3B | HTT 1294/4885BACE1 3822/4885MEN1 3027/4885 |
| US-20240002379-A1 | ASYMMETRIC CONJUGATE COMPOUNDS | TUBA1C, MTX2, CCNO | HTT 3874/4885BACE1 2819/4885MEN1 2682/4885 |
| US-11370801-B2 | Pyrrolobenzodiazepine conjugates | NR0B2, HRH3, NR0B1 | HTT 1179/4885BACE1 3031/4885MEN1 2980/4885 |
| US-20180291021-A1 | PDD COMPOUNDS | DRD1, DRD3, DRD2 | HTT 2338/4885BACE1 2908/4885MEN1 2579/4885 |
| US-20230143309-A1 | PYRROLOBENZODIAZEPINE ANTIBODY CONJUGATES | CD79B, H1-10, DRD1 | HTT 3365/4885BACE1 1980/4885MEN1 1578/4885 |
| US-11517626-B2 | Pyrrolobenzodiazepine antibody conjugates | CD79B, DRD1, H1-10 | HTT 3680/4885BACE1 1711/4885MEN1 1532/4885 |
| US-11912700-B2 | Anti-proliferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | MKI67, CCND2, CCND1 | HTT 3377/4885BACE1 2243/4885MEN1 2336/4885 |
| US-20170340752-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | CD22, GABRA1, CCNB1 | HTT 4023/4885BACE1 1497/4885MEN1 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.